| Current
Medicinal Chemistry
ISSN: 0929-8673

Current Medicinal Chemistry
Volume 17, Number 18, 2010
Contents

Plant and Animal Steroids a New Hope to Search for Antiviral
Agents Pp. 1858-1873
V. Castilla, J. Ramírez and C.E. Coto
[Abstract]
[Purchase
Article] [PMID: 20377516 PubMed - indexed for MEDLINE]
Dipyridodiazepinone Analogs as Human Immunodeficiency Virus
Type 1-Specific Non-Nucleoside Reverse Transcriptase Inhibitors:
An Overview Pp. 1874-1898
M. Lv and H. Xu
[Abstract]
[Purchase
Article] [PMID: 20377515 PubMed - indexed for MEDLINE]
Recognition of Nucleic Acids by Toll-Like Receptors and Development
of Immunomodulatory Drugs Pp. 1899-1914
A. Kunik, G. Panter and R. Jerala
[Abstract]
[Purchase
Article] [PMID: 20377514 PubMed - indexed for MEDLINE]
Editor’s
Choice
The Emerging Role of Nitrite as an Endogenous Modulator
and Therapeutic Agent of Cardiovascular Function
Pp. 1915-1925
B. Tota, A.M. Quintieri and T. Angelone
[Abstract]
[Purchase
Article] [PMID: 20377513 PubMed - indexed for MEDLINE]
The Chemistry of Mycophenolic Acid – Synthesis and Modifications
Towards Desired Biological Activity Pp. 1926-1941
G. Cholewinski, M. Malachowska-Ugarte and
K. Dzierzbicka
[Abstract]
[Purchase
Article] [PMID: 20377512 PubMed - indexed for MEDLINE]
Riluzole, Neuroprotection and Amyotrophic Lateral
Sclerosis Pp. 1942-1959
B.C. Cheah, S. Vucic, A.V. Krishnan and M.C.
Kiernan
[Abstract]
[Full
Text Article] [PMID: 20377511 PubMed - indexed for MEDLINE]
Quinoline-Based Antifungals Pp. 1960-1973
R. Musiol, M. Serda, S. Hensel-Bielowka and J.
Polanski
[Abstract]
[Purchase
Article] [PMID: 20377510 PubMed - indexed for MEDLINE]
Phytoecdysteroids and Vitamin D Analogues –
Similarities in Structure and Mode of Action Pp.
1974-1949
Noémi Tóth, Attila Hunyadi, Mária
Báthori and Erno Zádor
[Abstract]
[Purchase
Article] [PMID: 20377509 PubMed - indexed for MEDLINE]
Abstracts

[Back to top]
[Purchase
Article] [PMID: 20377516 PubMed - indexed for MEDLINE]
Plant and Animal Steroids a New Hope to Search for
Antiviral Agents
V. Castilla, J. Ramírez and C.E. Coto
Scientific literature provides evidence about the use of steroids
as an adjunct treatment to antiviral therapies. Immunomodulatory
activity of some steroids would account for the recovery in
patients with herpetic and other viral infections. However,
in vitro studies have demonstrated a direct antiviral
effect of this kind of molecules. In this review we discuss
recent reports about the mechanism of antiviral action of
steroids from animal and plant origin. Chemical structures
of most active compounds are also provided.
[Back to top] [Purchase
Article] [PMID: 20377515 PubMed - indexed for MEDLINE]
Dipyridodiazepinone Analogs as Human Immunodeficiency Virus
Type 1-Specific Non-Nucleoside Reverse Transcriptase Inhibitors:
An Overview
M. Lv and H. Xu
According to World Health Organization (WHO)/Joint United
Nations Programme on human immunodeficiency virus (HIV)/acquired
immune deficiency syndrome (AIDS) (UNAIDS) Report
in 2007, 33.2 million people are living with HIV, 2.5 million
ones have been newly infected with HIV, and 2.1 million ones
died from AIDS, including 330,000 children. Therefore, HIV/AIDS
still remains a public health emergency and a leading cause
of mortality worldwide. It is believed that reverse transcriptase
(RT) is a crucial enzyme in the life cycle of HIV-1, and thereby
RT has been the important drug target for antiretroviral (ARV)
chemotherapy against AIDS. To our knowledge, dipyridodiazepinone
analogs have been considered as one class of potential non-nucleoside
reverse transcriptase inhibitors (NNRTIs), especially the
structurally and chemically related nevirapine (Viramune®),
which was the first NNRTI approved by the U. S. Food and Drug
Administration (FDA) for the treatment of HIV-1 infection
for adults in 1996 and for children in 1998. This review mainly
highlights the progress of synthesis and structure–activity
relationship (SAR) of dipyridodiazepinone analogs; in the
meantime, the mechanism of action is also presented. It will
pave the way for the design and development of novel dipyridodiazepinone
analogs as NNRTIs in AIDS chemotherapy in the future.
[Back to top]
[Purchase
Article] [PMID: 20377514 PubMed - indexed for MEDLINE]
Recognition of Nucleic Acids by Toll-Like Receptors and Development
of Immunomodulatory Drugs
A. Kunik, G. Panter and R. Jerala
Microbial as well as endogenous nucleic acids are recognized
by a group of endosomal Toll-like receptors TLR3, TLR7, TLR8
and TLR9. Recent discoveries significantly improved our understanding
of molecular mechanism of their activation and their physiological
role. Those include recognition of dsRNA through two nucleic
acid binding sites of TLR3 ectodomain, activation of TLR9
by phosphodiester backbone of ssDNA, independent of the nucleotide
sequence and phosphorothioate modified bonds, and the role
of proteolysis in activation of TLR9. In addition, proteins
that chaperone nucleic acids, such as HMGB1 or LL-37, have
been described to mediate TLR activation. There is growing
evidence that supports involvement of endosomal TLRs in a
number of autoimmune diseases, suggesting a therapeutic potential
of immunomodulatory endosomal TLR ligands. So far, inhibitory
nucleic acids against TLR7, TLR8 and TLR9 as well as small
compounds targeting downstream signal transduction of single
or several endosomal TLRs have been reported. TLR-targeting
drugs have been included in clinical trials as vaccine adjuvants
or as therapeutic agents for the treatment of diseases, ranging
from cancer, infections, asthma and allergy to autoimmune
diseases.
[Back to top]
[Purchase
Article] [PMID: 20377513 PubMed - indexed for MEDLINE]
The Emerging Role of Nitrite as an Endogenous Modulator
and Therapeutic Agent of Cardiovascular Function
B. Tota, A.M. Quintieri and T. Angelone
Recently, the circulating anion nitrite (NO2-),
the largest physiological reservoir of nitric oxide (NO) in
the body, has revealed itself as a signalling molecule mediating
numerous biological responses. Since it was estimated that
as much as 70% of plasma nitrite originates from nitric oxide
synthases (NOSs), mainly in the endothelium by endothelial
NOS, nitrite is considered an index of NOSs activity. Exogenous
sources, principally environmental pollutants and intake of
vegetables, also contribute to this NO reserve. In mammalian
blood, nitrite, present at nanomolar concentrations, can be
reduced to bioactive NO along a physiological oxygen and pH
gradient either non-enzymatically (acidic disproportionation)
or by a number of enzymes including xanthine oxidoreductase,
NOS, mitochondrial cytochromes and deoxygenated haemoglobin
and myoglobin. The various NO-dependent nitrite-induced biological
responses include hypoxic vasodilation, inhibition of mitochondrial
respiration, cytoprotection following ischemia/reperfusion,
and regulation of protein and gene expression.
Since NO is a major paracrine-autocrine cardiovascular modulator
and nitrite acts mainly as an endocrine store of NO, it is
not surprising that NO2-
exerts important cardiovascular actions both under normal
and physio-pathological conditions.
In the interdisciplinary framework of the NO cycle concept,
this review illustrates the actions exerted by nitrite on
the cardiovascular system. Since the majority of the NO2-
-oriented studies focused on the systemic and regional control
of blood flow both under physiological and ischemia/reperfusion
conditions, we will firstly consider this issue. Secondly,
the nitrite-induced effects on myocardial contractile and
relaxation processes will be discussed, emphasizing the biomedical
interest of nitrite as a new therapeutic agent. The importance
of cardiac myoglobin as nitrite-reductase able to exert cardioprotection
through a novel function, in addition to its role as classical
respiratory protein, will be highlighted. Finally, using recent
data from others and our labs, we will emphasize the importance
of fish and amphibian heart models with diverse morphologies
and blood supply for providing remarkable insights on “ancestral”
functions of the nitrite-NO system in vertebrates, which,
in turn, may help to expand its actual significance in human
physiology.
[Back to top] [Purchase
Article] [PMID: 20377512 PubMed - indexed for MEDLINE]
The Chemistry of Mycophenolic Acid – Synthesis and Modifications
Towards Desired Biological Activity
G. Cholewinski, M. Malachowska-Ugarte and
K. Dzierzbicka
Mycophenolic acid (MPA) is a basis for the immunosuppressive
drugs used in clinic against rejection in solid organs transplantations.
Since its physiological activity is very promising, numerous
studies have been performed to establish mechanism of action,
structure – activity relationship (SAR), synthesis of
MPA derivatives to improve or extent its clinical use to anticancer
one, especially. The reported methods for preparation of MPA
analogues have been achieved by semi-synthetic approaches
or total synthesis and accomplished by in vitro or
/ and in vivo evaluations. In this review we would
like to bring together chemical aspects of these compounds
and their implementations within biological activity, their
synthesis and structural modifications referred to the structure-activity
relationship (SAR).
[Back to top]
[Full
Text Article] [PMID: 20377511 PubMed - indexed for MEDLINE]
Riluzole, Neuroprotection and Amyotrophic Lateral
Sclerosis
B.C. Cheah, S. Vucic, A.V. Krishnan and M.C.
Kiernan
Amyotrophic lateral sclerosis (ALS) is a universally
fatal neurodegenerative disease of the human motor system.
Aetiological mechanisms implicated in the development of ALS
have been linked to the glutamatergic neurotransmitter system,
with destruction of motor neurons triggered through excessive
activation of glutamate receptors at the synaptic cleft. This
‘excitotoxicity’ theory of ALS gave rise to the
development of therapeutic approaches and ultimately clinical
trials involving riluzole, initially thought to act solely
as an inhibitor of glutamate release. Subsequent effects of
riluzole have been postulated to include indirect antagonism
of glutamate receptors, in addition to inactivation of neuronal
voltage-gated Na+ channels.
Riluzole remains the only disease-modifying therapy available
to patients with ALS. Despite having been clinically available
since the mid-1990s, the in vivo pharmacological
targets of riluzole have been poorly defined. An improved
understanding concerning the potential neuroprotective mechanisms
of riluzole may unearth pathophysiological processes that
mediate neurodegeneration in ALS. The present review summarises
the known chemical and pharmacological properties of riluzole.
The failure of other putative neuroprotective therapies to
demonstrate positive treatment outcomes in this intractable
disease will be reviewed. Finally, the hypothesis that Na+
conductances may be involved in the processes of neuronal
and axonal degeneration in ALS will be explored.
[Back to top]
[Purchase
Article] [PMID: 20377510 PubMed - indexed for MEDLINE]
Quinoline-Based Antifungals
R. Musiol, M. Serda, S. Hensel-Bielowka and J.
Polanski
Although the assortment of antifungal drugs is broad,
the most commonly used agents have major drawbacks. Toxicity,
serious side effects or the emergence of drug resistance are
amongst them. New drugs and drug candidates under clinical
trials do not guarantee better pharmacological parameters.
These new medicines may appear effective; however; they may
cause serious side effects. This current review is focused
on the recent findings in the design of quinoline based antifungal
agents. This field seems to be especially interesting as 8-hydroxyquinoline
and its metal complexes have been well known as antifungals
for years. Structural similarities between quinoline based
antifungals and allylamines or homoallylamines, e.g. terbinafine
is another interesting fact. Quinoline can be identified in
a number of synthetic and natural antifungals, which indicates
nature’s preference for this fragment and identifying
it as one of the so-called privileged structures. We have
discussed new trends in the design of quinolines with antifungal
properties, their possible targets and the structure activity
relationships within the antifungal series developed.
[Back to top]
[Purchase
Article] [PMID: 20377509 PubMed - indexed for MEDLINE]
Phytoecdysteroids and Vitamin D Analogues –
Similarities in Structure and Mode of Action
Noémi Tóth, Attila Hunyadi, Mária
Báthori and Erno Zádor
Phytoecdysteroids are plant steroids with identical or
analogue structures to the molting hormone in arthropods.
The ecdysteroids exert several beneficial effects on mammals,
from which the most cited and deeply examined one is the increase
of muscle size and strength. This shows similarities with
the mode of action of the androgenic steroids but the ecdysteroids
do not bind to the cytoplasmic/nuclear receptor of the mammalian
steroids. These findings led to the hypothesis that ecdysteroids
possibly bind to membrane bound receptors and they are likely
to influence signal transduction pathways. Probably because
of their closely related chemical structures, ecdysteroids
exert some similar effects in vertebrates to those of the
hormone 1α,25-dihydroxyvitamin
D3 (1,25D) which is produced
in the kidney from 25-hydroxyvitamin D3,
after being converted in the liver from Vitamin D3.
1,25D generates biological responses via both genomic
and rapid, nongenomic mechanisms. Structure-activity relationship
studies with different Vitamin D analogues could open the
possibility to show that the two ways of action (genomic and
nongenomic) can be influenced separately.
The connection between the Vitamin D status and muscle function
is already well-described in clinical studies, and several
efforts have been made to evaluate the effect of Vitamin D
deficiency or supplementation on muscle morphological changes
and the underlying molecular mechanisms.
This paper aims to summarize the main structural commonalities
between the ecdysteroids, 1,25D and other Vitamin D analogues.
The similarities in their effects and pathways that might
be involved in the mechanism of action of these compounds
will also be discussed.
|